United States Patent 10,646,481 scope and claims for amorphous solid dispersion composition
Patent 10,646,481 is an FDA-relevant, formulation-centric US patent that protects a highly specific amorphous/“substantially amorphous” solid dispersion of a single defined API (Compound 1: N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide), in a defined matrix (HPMCAS + sodium lauryl sulfate), and a defined tablet composition with tightly bounded excipient ranges and specific mechanical property and API loadouts.
Core enforcement hook: claim 1 combines (i) crystallinity limits (<15% crystalline; and dependent claims tighten to <5%) with (ii) exact wt% of dispersion components (80% Compound 1, 19.5% HPMCAS, 0.5% SLS) and (iii) downstream tablet formulations/processing attributes (hardness ±20%, specific mg strengths, and specified excipients).
Freedom-to-operate risk: generic and reformulation entrants that change any of the following likely fall outside the claim scope: the solid dispersion composition ratios, the amorphous/crystalline specification, the defined SLS level (both in dispersion and in the overall composition/tablet), and the tablet excipient ranges/binders/disintegrants/lubricants/glidants.
What does US Patent 10,646,481 claim, and what is the protected formulation?
Direct answer (claim center): US 10,646,481 claims a pharmaceutical composition containing a solid dispersion where the dispersion is specifically:
- 80 wt% amorphous or substantially amorphous Compound 1
- 19.5 wt% hydroxypropylmethylcellulose acetate succinate (HPMCAS)
- 0.5 wt% sodium lauryl sulfate (SLS)
with substantially amorphous Compound 1 defined by crystallinity <15%, then compositions and tablets containing specific additional excipients and ranges.
How claim 1 is structured legally
Claim 1 is a composition claim with a required sub-structure:
- “A pharmaceutical composition comprising a solid dispersion”
- Solid dispersion must contain three components at specified wt%
- Crystallinity constraint on Compound 1 inside that dispersion
- The claim does not stop at the dispersion; it contemplates further tablet/composition features through dependent claims (claims 2–13, 14–26).
Key claim elements for scope and infringement
- API identity: “N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1).”
- Solid dispersion architecture: API dispersed in polymeric amorphous matrix (HPMCAS) with SLS.
- Crystalline content metric: “substantially amorphous” = <15% crystalline (then dependent tightening to <5%).
- Quantitative matrix: 80% / 19.5% / 0.5% by weight of dispersion.
- Downstream formulations: tablet excipients and ranges plus hardness and mg strength.
How do the amorphous/crystalline limitations affect claim scope (15% vs 5% crystalline)?
Direct answer: The claims use objective crystallinity thresholds to define “substantially amorphous Compound 1.” The independent claim uses <15% crystalline, while multiple dependent claims tighten to <5% crystalline.
Claim 1 crystallinity threshold
- Claim 1: substantially amorphous Compound 1 comprises less than 15% crystalline Compound 1.
Tighter dependent crystallinity scope
- Claim 13: substantially amorphous Compound 1 comprises less than 5% crystalline Compound 1.
- Claim 15: tablet claim with <5% crystalline.
- Claim 17: composition claim with <5% crystalline (and an explicit full recipe).
Practical legal impact
Crystallinity thresholds are often the largest technical boundary in formulation patents. Any generic/reformulation strategy that produces:
- materially higher crystallinity (≥15%) in the “solid dispersion” product, or
- amorphous content achieved through different carrier systems that do not match the defined dispersion composition,
creates a plausible claim-scope exit for at least the “solid dispersion” elements.
What are the exact dispersion component ratios protected by US 10,646,481?
Direct answer: The protected solid dispersion has a fixed wt% recipe: 80% Compound 1, 19.5% HPMCAS, 0.5% SLS (all by weight of the dispersion).
Exact wt% in dispersion (hard requirement)
- 80% Compound 1 (amorphous/substantially amorphous; crystallinity <15% in claim 1)
- 19.5% HPMCAS
- 0.5% SLS
Why fixed ratios matter for design-arounds
A potential design-around must change at least one of:
- polymer type, polymer grade, or polymer proportion (replace HPMCAS, alter wt%)
- surfactant system or SLS level in the dispersion
- solid dispersion definition (e.g., co-amorphous system or spray-dried dispersion with different excipient package)
Because the dispersion composition is recited as exact wt%, altering the dispersion’s component proportions likely forces a non-infringing position, assuming claim interpretation stays literal.
How do the dependent claims expand scope beyond the dispersion (which excipients, and at what levels)?
Claims 2–7: additional composition components
Claim 2: adds
- 30.5% microcrystalline cellulose by weight of the composition.
Claim 3: adds
- 30.4% lactose by weight of the composition.
Claim 4: adds
- 3% sodium croscarmellose by weight of the composition.
Claim 5: adds (note: duplicates SLS concept at composition level)
- 0.5% SLS by weight of the composition.
Claim 6: adds
- 0.5% colloidal silicon dioxide by weight of the composition.
Claim 7: adds
- 1.0% magnesium stearate by weight of the composition.
In short: claims 2–7 build toward a very specific tablet-like composition recipe, even before claim 14’s formal tablet ranges.
Claim 8: coating
- “wherein the composition further comprises a coating.”
This is broad in wording but depends on how “coating” is interpreted in prosecution history and claim construction.
Claim 9: mechanical property limitation
- hardness 98 N (10 kp) ±20 percent.
This is a tangible, testable limit that can constrain infringement to product-measured hardness within the claimed band.
Claims 10–11: API strength examples
- claim 10: contains 150 mg Compound 1
- claim 11: contains 100 mg Compound 1
Claim 12: fixed solid dispersion fraction in the composition
- “comprising 34.1% of the solid dispersion by weight of the composition.”
Claim 16: full enumerated composition recipe
Claim 16 recites the same fixed dispersion and a full excipient list with precise wt% values:
- 34.1 wt% solid dispersion consisting of (80% Compound 1 / 19.5% HPMCAS / 0.5% SLS)
- 30.5% microcrystalline cellulose
- 30.4% lactose
- 3% sodium croscarmellose
- 0.5% SLS
- 0.5% colloidal silicon dioxide
- 1.0% magnesium stearate
And claim 17 tightens crystallinity to <5%.
What tablet composition ranges does US 10,646,481 protect (percent ranges vs fixed amounts)?
Direct answer: Claim 14 protects a tablet where the solid dispersion is 30%–50% of the tablet, and other excipients sit in bounded ranges for filler/disintegrant/surfactant/binder/glidant/lubricant.
Claim 14: tablet with range-based excipient architecture
Tablet must include:
- Solid dispersion: 30%–50% by weight of tablet
- dispersion must still be: 80% Compound 1, 19.5% HPMCAS, 0.5% SLS
- and Compound 1 in the dispersion must have crystallinity <15% (claim 14 uses that threshold via incorporation from claim 1 language)
- Filler: 25%–50%
- Disintegrant: 1%–10%
- Surfactant: 0.3%–2%
- Binder: 20%–45%
- Glidant: 0.09%–1.0%
- Lubricant: 0.1%–2%
Claim 15: crystallinity tightens within the tablet
- Claim 15 is claim 14 with substantially amorphous Compound 1 <5%.
Claims 18–26: tablet-specific fixed recipe
Claims 18–26 recast tablet claims around:
- tablet formulation requirement (claim 18),
- specific excipient levels that mirror the fixed composition recipe (claims 19–24),
- and solid dispersion content fixed at 34.1% (claims 25–26).
What is the claimed API loadout and hardness window, and why it matters for infringement?
API loadouts
The claims explicitly list:
- 100 mg Compound 1 (claim 11)
- 150 mg Compound 1 (claim 10)
These function as example-strength limitations in those dependent claims. Their enforcement depends on which claim(s) are asserted and on whether claim interpretation limits protection to those strengths.
Hardness limitation
- 98 N (10 kp) ±20% (claim 9)
This ties infringement to a measured mechanical property band. If a generic tablet uses a structurally identical formulation but lands outside the hardness band, it may avoid claim 9 while still potentially implicating other broader claims (such as those without hardness limits).
How does claim 16 relate to claim 14 (range-based vs fixed recipe)?
Core distinction:
- Claim 14: tablet with ranges (solid dispersion 30%–50%, excipients with broad bands).
- Claim 16: composition with fixed amounts (solid dispersion fraction 34.1%, and exact wt% excipients).
Implication for coverage:
- Range claims (14/15) provide broader coverage across manufacturing variability, but still require the solid dispersion recipe and crystallinity threshold.
- Fixed claims (16/17 and tablet fixed claims 19–26) provide narrower but more precise patent “anchors” for enforcement on a known formulation.
What does the patent landscape likely look like around US 10,646,481 (composition/formulation estate dynamics)?
Within this patent’s scope: the claims are built around:
- a single defined API (Compound 1),
- a single polymer (HPMCAS),
- a single surfactant (SLS),
- and quantified crystallinity targets.
Common surrounding risks for competitors
Even without citing other patents here (not provided in your prompt), this claim structure implies typical adjacent IP buckets competitors face in practice:
- Earlier process/polymorph or amorphous generation patents for Compound 1 (how amorphous material is made and characterized).
- Solid dispersion patents for various polymer/surfactant combinations.
- Tablet excipient and mechanical property patents for specific granulation/compression and hardness/disintegration targets.
- Bioavailability and stability patents tied to the amorphous dispersion in HPMCAS + SLS systems.
For infringement, a challenger must map their candidate product’s:
- dispersion composition,
- crystallinity outcome,
- and tablet recipe and mechanical properties
to the recited claim boundaries.
Which claim elements are most likely to be litigated (technical claim construction pressure points)?
- Definition of “substantially amorphous”
- “less than 15% crystalline” and “less than 5% crystalline”
- requires consistent testing method and interpretation (XRD peak assignment, DSC, Rietveld, etc. under claim construction).
- Whether solids in the final product are truly the claimed “solid dispersion”
- dispersion composition is by weight of the dispersion, not necessarily by weight of total tablet, and is a frequent source of arguments about basis of measurement.
- Weight basis and accounting
- claim 1: wt% in the dispersion
- claim 2–7 and 16: wt% in the overall composition
- claim 14: wt% of tablet
These can drive non-infringement arguments if competitors model formulation mass differently.
- Hardness limitation
- claim 9 adds a product attribute that can be measured and can be engineered during manufacturing.
What are the likely “design-around” strategies implied by the claim language?
Because the claims are tightly quantitative, plausible non-infringing routes generally involve:
- Changing the dispersion wt% recipe (not 80/19.5/0.5 by dispersion weight).
- Switching away from HPMCAS (or changing its wt%).
- Removing or replacing SLS, or altering SLS to be outside the dispersion and/or tablet composition boundaries.
- Producing a dispersion with crystallinity ≥15% (to exit claim 1 and 14/15) or ≥5% (to exit the tighter dependent claims).
- Changing tablet excipient ranges or fixed excipient levels (claims 2–7, 19–24, 25–26, and claim 14’s range boundaries).
- Moving hardness outside 98 N ±20% if claim 9 is targeted.
Claim-by-claim scope map (what each claim adds vs claim 1)
| Claim |
What it covers |
Hard boundary requirements |
| 1 |
Pharmaceutical composition with defined solid dispersion |
Dispersion recipe (80% Compound 1 / 19.5% HPMCAS / 0.5% SLS); Comp 1 crystallinity <15% |
| 2 |
Composition adds microcrystalline cellulose |
30.5% MCC by weight of composition |
| 3 |
Composition adds lactose |
30.4% lactose by weight |
| 4 |
Composition adds sodium croscarmellose |
3% by weight |
| 5 |
Composition adds SLS |
0.5% by weight of composition (in addition to SLS in dispersion) |
| 6 |
Composition adds colloidal silicon dioxide |
0.5% by weight |
| 7 |
Composition adds magnesium stearate |
1.0% by weight |
| 8 |
Composition includes coating |
“further comprises a coating” |
| 9 |
Hardness-limited composition |
98 N (10 kp) ±20% |
| 10 |
Strength example |
150 mg Compound 1 |
| 11 |
Strength example |
100 mg Compound 1 |
| 12 |
Solid dispersion fraction fixed |
34.1% solid dispersion by weight of composition |
| 13 |
Tightens crystallinity |
Compound 1 crystallinity <5% |
| 14 |
Tablet with range-based excipients + solid dispersion |
Dispersion recipe as in claim 1; dispersion is 30%–50% of tablet; other excipients in ranges |
| 15 |
Tightens crystallinity in tablet |
Compound 1 crystallinity <5% |
| 16 |
Composition with full fixed recipe |
34.1 wt% solid dispersion; exact excipient wt% list; crystallinity not yet tightened unless via claim 17 |
| 17 |
Tightens crystallinity for claim 16 recipe |
Compound 1 crystallinity <5% |
| 18 |
Composition formulated as tablet |
tablet format requirement |
| 19–24 |
Tablet excipients at fixed levels |
MCC 30.5%, lactose 30.4%, croscarmellose 3%, SLS 0.5%, colloidal SiO2 0.5%, Mg stearate 1.0% |
| 25–26 |
Tablet with fixed solid dispersion fraction |
34.1% solid dispersion by weight |
Key takeaways
- US 10,646,481 is dominated by a rigid solid dispersion recipe: Compound 1 (80%) + HPMCAS (19.5%) + SLS (0.5%), with crystallinity defined as <15% (and dependent claims <5%).
- Tablet protection spans both range claims (claim 14: multiple excipients with broad percent bands; dispersion 30%–50% of tablet) and fixed-amount claims (claims 16 and 19–26: exact excipient wt% values, fixed 34.1% dispersion fraction).
- The patent includes measurable product attribute limits: hardness 98 N (10 kp) ±20%, and explicit strength examples (100 mg, 150 mg).
- The highest-risk infringement pathways are products that reproduce the solid dispersion wt% ratios and achieve the claimed crystallinity in that dispersion, then use a matching tablet excipient package.
FAQs
1) Does US 10,646,481 require the tablet to have the same hardness as the example?
Only claim 9 imposes a hardness limitation; other claims cover compositions/tablets without the hardness parameter.
2) If a product matches the dispersion recipe but uses a different polymer than HPMCAS, does it still infringe?
Not on the literal terms of claims that require the dispersion to contain 19.5 wt% HPMCAS (claim 1/14 and downstream dependent coverage that incorporates the same dispersion definition).
3) Can a product escape the patent by producing Compound 1 with crystallinity above 15% in the dispersion?
It can potentially exit claim 1/14 scope by failing the “substantially amorphous” threshold of <15% crystalline.
4) Are SLS levels claimed twice in the final product?
Yes. SLS is required within the dispersion (0.5% by dispersion weight in claim 1), and dependent claims also require 0.5% SLS by composition weight (claim 5) and corresponding fixed tablet values (claim 22).
5) Which claim set offers broader protection: the tablet range claims or the fixed composition claims?
Claim 14’s range-based tablet construction is broader on excipient proportions, while claims 16/19–26 are narrower but more precise due to exact wt% recitations.
References
- United States Patent 10,646,481. (as provided in user prompt: claim set and text of claims 1–26).
